Spain, which will receive two batches of eight million doses of the formula, expects to begin inoculations within a month
No surprises. The European Medicines Agency at its meeting this morning in Amsterdam has given the green light to the use in the EU of Moderna’s vaccine. The Ministry of Health hopes to be able to give a “strong boost” to the vaccination campaign against covid with the arrival of the first vials of this vaccine which will be added to Pfizer products, the only two so far being distributed in the European Union.
After the controversy over the shortage of inoculations during the first week, the Ninistry of Health hopes to significantly increase the rate with the incorporation of mRNA-1273, Moderna’s formula that is almost identical in effectiveness to that of Pfizer, with a percentage of immunity close to 95% of immunisation.
The Minister says that injectables will arrive in Spain within a month following this morning’s decision by the European Medicines Agency.
The European Commission has purchased a total of 160 million vials of mRNA-1273, divided into two batches. As in the case of Pfizer, Spain is assigned by its population approximately one tenth of these, that is, about 16 million injectables that, being also double-dose, will immunise 8 million people. For Moderna, the booster dose should be administered one month after the first.
Experts believe that the arrival, delivery and use of Moderna’s vaccines will be much easier than that of Pfizer, not only because of the experience already acquired, but also because mRNA-1273 allows the transport and storage of the vaccine in its normal state. liquid at a temperature between +2 degrees and -8 degrees, so conventional freezers are enough for its storage, an advantage over the Pfizer compound that requires freezers at temperatures of 70 degrees below zero.
Although they have not yet requested a license for their vaccines, the European Medicines Agency is also studying in real time the data shared by the British company AstraZeneca and the University of Oxford, on the one hand, and Janssen, a subsidiary of the American Johnson & Johnson, on the other, in anticipation of being asked for a provisional marketing authorisation in the coming weeks.